Ponatinib was structurally designed to inhibit BCR-ABL and the BCR-ABL T315I point mutation variant that confer resistance to existing tyrosine kinase inhibitors in chronic myeloid leukemia [44]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.